阿普司特抑制TNFα诱导的人内皮细胞血管炎症
本研究探讨磷酸二酯酶4抑制剂阿普司特对TNFα激活的人脐静脉内皮细胞(HUVEC)促炎反应的影响。结果显示阿普司特抑制TNFα诱导的GM-CSF、CXCL10、CCL2、VCAM-1、E-selectin和MMP9表达与分泌,减少THP-1细胞黏附和跨内皮迁移,并抑制NFκB和MAPK信号活化。
要点
- 阿普司特抑制TNFα诱导的内皮细胞促炎因子和黏附分子表达。
- 阿普司特减少单核细胞向内皮细胞的黏附和跨内皮迁移。
- 机制涉及抑制NFκB和MAPK信号通路活化。
核心结论
- 阿普司特在激活的HUVEC中具有明确的抗炎作用,可能有助于降低慢性炎症性疾病患者的心血管疾病风险。
研究设计与样本
- 体外实验研究,使用TNFα激活的人脐静脉内皮细胞(HUVEC),检测阿普司特对炎症因子表达、黏附与跨内皮迁移及信号通路的影响。
主要发现
- 阿普司特抑制TNFα诱导的GM-CSF、CXCL10、CCL2、VCAM-1、E-selectin和MMP9表达与分泌。
- 阿普司特减少THP-1单核细胞对激活HUVEC的黏附和跨内皮迁移。
- 阿普司特抑制激活HUVEC中NFκB和MAPK信号活化。
- 抑制p38、JNK和NFκB可降低激活HUVEC中GM-CSF、VCAM-1和E-selectin表达。
- 阿普司特降低IL-17A诱导的IL-6和CCL2分泌。
临床怎么用
- 提示阿普司特在控制皮肤炎症之外可能具有改善内皮炎症的潜在益处。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with chronic inflammatory diseases (e.g. psoriasis and rheumatoid arthritis) are at increased risk for the development of atherosclerosis and cardiovascular diseases (CVD). Previous studies have suggested that phosphodiesterase 4 (PDE4) inhibitors possess anti-inflammatory properties. OBJECTIVES: Here we examined the effect of the PDE4 inhibitor apremilast, a well-established anti-psoriatic drug, on pro-inflammatory responses in TNFα-activated endothelial cells. METHODS: Human umbilical vein endothelial cells (HUVEC) were treated with tumour necrosis factor-α (TNFα) in the presence or absence of apremilast. Expression levels of pro-inflammatory cytokines, chemokines and adhesion molecules were assessed by ELISA, western blot and RT-PCR. Effects of apremilast on adhesion and transendothelial migration (TEM) of THP-1 monocytic cells were analysed in transwell assays. RESULTS: Apremilast suppressed TNFα-induced expression and secretion of important endothelial and monocytic pro-inflammatory factors, including granulocyte-macrophage colony-stimulating factor (GM-CSF), C-X-C motif chemokine ligand 10 (CXCL10), chemokine (C-C motif) ligand 2 (CCL2), vascular cell adhesion molecule 1 (VCAM-1), E-selectin and matrix metalloproteinase-9 (MMP9). Functionally, apremilast reduced adhesion of THP-1 cells to activated HUVECs and TEM in response to TNFα. Mechanistically, apremilast suppressed activation of nuclear factor κB (NFκB) and mitogen-activated protein kinases (MAPK) signalling in activated HUVECs. Furthermore, inhibition of p38, C-Jun-N-terminale Kinase (JNK) and NFκB in activated HUVECs decreased expression of GM-CSF, VCAM-1 and E-selectin. Additionally, apremilast decreased IL-17A-induced secretion of IL-6 and CCL2. CONCLUSIONS: We demonstrate that apremilast has distinct anti-inflammatory effects in activated HUVECs, indicating that apremilast could have the therapeutic potential to prevent higher risk for CVD in patients with chronic inflammatory diseases.
引用
- Otto M, Dorn B, Grasmik T, et al. Apremilast effectively inhibits TNFα-induced vascular inflammation in human endothelial cells. J Eur Acad Dermatol Venereol. 2021. PMID: 34699634. doi:10.1111/jdv.17769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。